Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers
Issued Date
2024-08-01
Resource Type
eISSN
14712334
Scopus ID
2-s2.0-85200433103
Pubmed ID
39090537
Journal Title
BMC infectious diseases
Volume
24
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMC infectious diseases Vol.24 No.1 (2024) , 768
Suggested Citation
Suwarti S., Lazarus G., Zanjabila S., Sinto R., Fransiska F., Deborah T., Oktavia D., Junaidah J., Santayana S., Surendra H., Yuliana J., Pardosi H., Nuraeni N., Soebianto S., Susilowati N.D., Subekti D., Pradipta A., Baird J.K., Tan L.V., Dunachie S., Shankar A.H., Nelwan E.J., Hamers R.L., Anh N.T., Hong N.T.T., Truc T.H.C., Ny N.T.H., Han D.D.K., Thanh L.K., Nguyet L.A., Thuy C.T., Nhu L.N.T., Thanh T.T., Yen L.M., Hang V.T., Kieu P.T., Hoang V.T., Thao N.T., Chambers M., Thanh V.D., Hoang T.C., Thwaites C.L., Thwaites G., van Doorn H.R., Tung T.S., Mongkolsapaya J., Screaton G., Dijokaite-Guraliuc A., Das R., Liu C., Supasa P., Selvaraj M., Dunachie S., Klenerman P., Jones E.Y., Stuart D.I., Kronsteiner-Dobramysl B., Zewdie M., Abraham P., Hill J., Tayipto Y., Paramita I., Lin-Fa W., Wah T.C., Chee Y.W., Lee L.B., Suwarti, Simarmata E., Dien R., Dejnirattisai W., Chantima W., Chantratita N., Poolchanuan P., Tiacharoen V., Dulsuk A., Iamsirithaworn S., Day N., Cheah P.Y., Poomchaichote T., Boonthaworn K., Ngoc N.M., Grifoni A., Sette A. Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers. BMC infectious diseases Vol.24 No.1 (2024) , 768. doi:10.1186/s12879-024-09644-y Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/100443
Title
Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers
Author(s)
Suwarti S.
Lazarus G.
Zanjabila S.
Sinto R.
Fransiska F.
Deborah T.
Oktavia D.
Junaidah J.
Santayana S.
Surendra H.
Yuliana J.
Pardosi H.
Nuraeni N.
Soebianto S.
Susilowati N.D.
Subekti D.
Pradipta A.
Baird J.K.
Tan L.V.
Dunachie S.
Shankar A.H.
Nelwan E.J.
Hamers R.L.
Anh N.T.
Hong N.T.T.
Truc T.H.C.
Ny N.T.H.
Han D.D.K.
Thanh L.K.
Nguyet L.A.
Thuy C.T.
Nhu L.N.T.
Thanh T.T.
Yen L.M.
Hang V.T.
Kieu P.T.
Hoang V.T.
Thao N.T.
Chambers M.
Thanh V.D.
Hoang T.C.
Thwaites C.L.
Thwaites G.
van Doorn H.R.
Tung T.S.
Mongkolsapaya J.
Screaton G.
Dijokaite-Guraliuc A.
Das R.
Liu C.
Supasa P.
Selvaraj M.
Dunachie S.
Klenerman P.
Jones E.Y.
Stuart D.I.
Kronsteiner-Dobramysl B.
Zewdie M.
Abraham P.
Hill J.
Tayipto Y.
Paramita I.
Lin-Fa W.
Wah T.C.
Chee Y.W.
Lee L.B.
Suwarti
Simarmata E.
Dien R.
Dejnirattisai W.
Chantima W.
Chantratita N.
Poolchanuan P.
Tiacharoen V.
Dulsuk A.
Iamsirithaworn S.
Day N.
Cheah P.Y.
Poomchaichote T.
Boonthaworn K.
Ngoc N.M.
Grifoni A.
Sette A.
Lazarus G.
Zanjabila S.
Sinto R.
Fransiska F.
Deborah T.
Oktavia D.
Junaidah J.
Santayana S.
Surendra H.
Yuliana J.
Pardosi H.
Nuraeni N.
Soebianto S.
Susilowati N.D.
Subekti D.
Pradipta A.
Baird J.K.
Tan L.V.
Dunachie S.
Shankar A.H.
Nelwan E.J.
Hamers R.L.
Anh N.T.
Hong N.T.T.
Truc T.H.C.
Ny N.T.H.
Han D.D.K.
Thanh L.K.
Nguyet L.A.
Thuy C.T.
Nhu L.N.T.
Thanh T.T.
Yen L.M.
Hang V.T.
Kieu P.T.
Hoang V.T.
Thao N.T.
Chambers M.
Thanh V.D.
Hoang T.C.
Thwaites C.L.
Thwaites G.
van Doorn H.R.
Tung T.S.
Mongkolsapaya J.
Screaton G.
Dijokaite-Guraliuc A.
Das R.
Liu C.
Supasa P.
Selvaraj M.
Dunachie S.
Klenerman P.
Jones E.Y.
Stuart D.I.
Kronsteiner-Dobramysl B.
Zewdie M.
Abraham P.
Hill J.
Tayipto Y.
Paramita I.
Lin-Fa W.
Wah T.C.
Chee Y.W.
Lee L.B.
Suwarti
Simarmata E.
Dien R.
Dejnirattisai W.
Chantima W.
Chantratita N.
Poolchanuan P.
Tiacharoen V.
Dulsuk A.
Iamsirithaworn S.
Day N.
Cheah P.Y.
Poomchaichote T.
Boonthaworn K.
Ngoc N.M.
Grifoni A.
Sette A.
Author's Affiliation
Mahidol Oxford Tropical Medicine Research Unit
Oxford University Clinical Research Unit
Kementerian Kesehatan Republik Indonesia
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
Universitas Indonesia
Monash University
Nuffield Department of Medicine
Genomik Solidaritas Indonesia (GSI) Lab
Indonesian Medical Education and Research Institute
St. Carolus Hospital
Oxford University Clinical Research Unit
Kementerian Kesehatan Republik Indonesia
Universitas Indonesia, RSUPN Dr. Cipto Mangunkusumo
Universitas Indonesia
Monash University
Nuffield Department of Medicine
Genomik Solidaritas Indonesia (GSI) Lab
Indonesian Medical Education and Research Institute
St. Carolus Hospital
Corresponding Author(s)
Other Contributor(s)
Abstract
BACKGROUND: Data on the dynamics and persistence of humoral immunity against SARS-CoV-2 after primary vaccination with two-dose inactivated vaccine (CoronaVac) are limited. This study evaluated the sequential effects of prior infection, heterologous boosting with mRNA-1273 (Moderna), and the occurrence of Omicron vaccine-breakthrough infection (VBI) thereafter. METHODS: We evaluated anti-spike IgG (Abbott) and neutralising (cPASS/GenScript) antibody (nAb) titers up to one year after mRNA-1273 boost in two-dose-CoronaVac-primed Indonesian healthcare workers (August 2021-August 2022). We used linear mixed modeling to estimate the rate of change in antibody levels, and logistic regression to examine associations between antibody levels and VBI. RESULTS: Of 138 participants, 52 (37.7%) had a prior infection and 78 (56.5%) received an mRNA-1273 booster. After two-dose CoronaVac, antibody titers had significantly declined within 180 days, irrespective of prior infection. After mRNA-1273 booster, anti-spike IgG (1.47% decline/day) and Omicron B.1.1.529/BA.2 nAbs declined between day 28-90, and IgG titers plateaued between day 90-360. During the BA.1/BA.2 wave (February-March 2022), 34.6% (27/78) of individuals experienced a VBI (median 181 days after mRNA-1273), although none developed severe illness. VBI was associated with low pre-VBI anti-spike IgG and B.1.1.529/BA.2 nAbs, which were restored post-VBI. CONCLUSIONS: mRNA-1273 booster after two-dose CoronaVac did not prevent BA.1/BA.2 VBI. Periodic vaccine boosters may be warranted against emerging SARS-CoV-2 variants.